Expert forum

Primary pigmented nodular adrenocortical disease

Expand

Received date: 2023-05-30

  Online published: 2024-01-09

Cite this article

GU Yanyun, ZHOU Weiwei, WANG Weiqing, et al . Primary pigmented nodular adrenocortical disease[J]. Journal of Internal Medicine Concepts & Practice, 2023 , 18(04) : 230 -233 . DOI: 10.16138/j.1673-6087.2023.04.003

References

[1] Chute AL, Robinson GC, Donohue WL. Cushing’s syndrome in children[J]. J Pediatr, 1949, 34(1): 20-39.
[2] Shenoy BV, Carpenter PC, Carney JA, et al. Bilateral primary pigmented nodular adrenocortical disease[J]. Am J Surg Pathol, 1984, 8(5): 335-344.
[3] Pitsava G, Maria AG, Faucz FR. Disorders of the adrenal cortex: genetic and molecular aspects[J]. Front Endoc-rinol (Lausanne), 2022, 13: 931389.
[4] Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation[J]. J Clin Endocrinol Metab, 2001, 86(9): 4041-4046.
[5] Sahut-Barnola I, de Joussineau C, Val P, et al. Cushing’s syndrome and fetal features resurgence in adrenal cortex-specific PRKAR1A knockout mice[J]. PLoS Genet, 2010, 6(6): e1000980.
[6] Bertherat J, Horvath A, Groussin L, et al. Mutations in regulatory subunit type 1A of cyclic adenosine 5’-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes[J]. J Clin Endocrinol Metab, 2009, 94(6): 2085-2091.
[7] Berthon A, Bertherat J. Update of genetic and molecular causes of adrenocortical hyperplasias causing Cushing syndrome[J]. Horm Metab Res, 2020, 52(8): 598-606.
[8] Horvath A, Mericq V, Stratakis CA. Mutation in PDE8B, a cyclic AMP-specific phosphodiesterase in adrenal hyperplasia[J]. N Engl J Med, 2008, 358(7): 750-752.
[9] Horvath A, Boikos S, Giatzakis C, et al. A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia[J]. Nat Genet, 2006, 38(7): 794-800.
[10] Leedman PJ, Cohen AK, Matz LR. et al. The complex of myxomas, spotty pigmentation and endocrine overactivity[J]. Clin Endocrinol (Oxf), 1986, 25(5): 527-534.
[11] Bouys L, Bertherat J. Carney complex: clinical and genetic update 20 years after the identification of the CNC1(PRKAR1A) gene[J]. Eur J Endocrinol, 2021, 184(3): R99-R109.
[12] Faucz FR, Maria AG, Stratakis CA. Molecular tools for diagnosing diseases of the adrenal cortex[J]. Curr Opin Endocrinol Diabetes Obes, 2023, 30(3): 154-160.
[13] Kirschner LS, Carney JA, Pack SD, et al. Mutations of the gene encoding the protein kinase A type Ⅰ-alpha regulatory subunit in patients with the Carney complex[J]. Nat Genet, 2000, 26(1): 89-92.
[14] 顾燕云, 陈瑛, 宋怀东, 等. 一例家族性Camey综合征临床及分子生物学研究[J]. 中华内科杂志, 2004, 43(10): 764-768.
[15] Forlino A, Vetro A, Garavelli L, et al. PRKACB and Carney complex[J]. N Engl J Med, 2014, 370(11): 1065-1067.
[16] Bourdeau I, Lacroix A, Schürch W, et al. Primary pigmented nodular adrenocortical disease: paradoxical responses of cortisol secretion to dexamethasone occur in vitro and are associated with increased expression of the glucocorticoid receptor[J]. J Clin Endocrinol Metab, 2003, 88(8): 3931-3937.
[17] Vezzosi D, Tenenbaum F, Cazabat L, et al. Hormonal, radiological, NP-59 scintigraphy, and pathological correlations in patients with Cushing’s syndrome due to primary pigmented nodular adrenocortical disease(PPNAD)[J]. J Clin Endocrinol Metab, 2015, 100(11): 4332-4338.
[18] Mete O, Erickson LA, Juhlin CC, et al. Overview of the 2022 WHO classification of adrenal cortical tumors[J]. Endocr Pathol, 2022, 33(1): 155-196.
[19] Espiard S, Vantyghem MC, Assié G, et al. Frequency and incidence of Carney complex manifestations[J]. J Clin Endocrinol Metab, 2020, 105(3): dgaa002.
[20] Lodish M, Stratakis CA. A genetic and molecular update on adrenocortical causes of Cushing syndrome[J]. Nat Rev Endocrinol, 2016, 12(5): 255-262.
Outlines

/